Additional European Equity News
AJ Bell (AJB LN) - Announces the removal of its regular investing charge. (AJ Bell)
AstraZeneca (AZN LN) - Breztri approved in the US for asthma as first and only triple therapy for patients 12 years of age and older. (AstraZeneca)
Air Liquide (AI FP) - Q1 2026 (EUR): Revenue 6.79bln (exp. 6.92bln), Gas & Services Revenue 6.60bln (exp. 6.72bln), Comp Sales +1.9% (exp. +2.3%). Notes that the interruption of helium source in Qatar since March has had a limited impact on the co's Q1 performance. Affirms guidance. (Air Liquide)
Anglo American (AAL LN) - Q1 2026 Update: Copper 170kt (prev. 169kt Y/Y), Diamonds 7.1Mct (prev. 6.1Mct Y/Y). CEO: "While the conflict in the Middle East is creating considerable volatility in the broader market, our resilient supply chain is currently supporting business continuity, and we are actively managing the situation to address potential adverse effects, including cost inflation".
ASSA ABLOY (ASSAB SS) - Q1 2026 (SEK): Sales 35.75bln (exp. 35.8bln, prev. 37.94bln Y/Y), EBITA 5.85bln (prev. 6.05bln Y/Y), EBIT 5.46bln (prev. 5.64bln Y/Y), Net income 3.538bln (prev. 3.551bln Y/Y), EPS 3.18 (prev. 3.20 Y/Y). (ASSA ABLOY)
Barclays (BARC LN) - Q1 2026 (GBP): Revenue 8.16bln (prev. 7.7bln), Investment Bank Revenue 4.03bln (exp. 3.97bln) Profit Before Impairment 3.63bln (prev. 3.36bln) PBT 2.81bln (prev. 2.72bln) CET1 14.1% (prev. 14.3%). GBP 500mln buyback. CEO "...remain confident in delivering all our financial targets across a range of environments". (Barclays)
BP (BP/ LN) - Q1 2026 (USD): EPS 0.21 (exp. 0.17), Revenue 52.25bln (exp. 57.6bln), Adj. Net Income 3.20bln (exp. 2.64bln). Performance: "Strong upstream operations: 1Q 2026 upstream plant reliability improved to 95.7% (prev. 95.4% Y/Y); reported production broadly flat as higher production in the Gulf of America and strong performance in bpx Energy offset the impact of disruptions in the Middle East and a North Sea divestment at the end of 2025". "Continued strategic progress: announced agreement to sell Gelsenkirchen refinery. On transaction completion, our structural cost reduction target will increase by USD 1bln to USD 6.5-7.5bln by 2027". Q2'26 guidance: "Looking ahead, bp expects second quarter 2026 reported upstream production to be lower compared with the first quarter 2026, due to seasonal maintenance predominantly in the Gulf of America and the effects of disruption in the Middle East". 2026 guidance: "bp now expects reported upstream production to be lower due to effects of disruption in the Middle East and underlying upstream production to be broadly flat compared with 2025. Within this, bp expects underlying production from oil production & operations to be broadly flat and production from gas & low carbon energy to be lower". (BP)
Bayer (BAYN GY) - The US Supreme Court appeared divided over whether Bayer can be sued for failing to warn that its Roundup weedkiller may cause cancer, in a case that could determine the fate of thousands of lawsuits and billions in liability. (USA Today)
Coca Cola HBC (CCEP LN) - Q1 2026 (EUR): Revenue 5bln (prev. 4.69bln Y/Y). Affirms guidance. (Coca Cola HBC)
Engie (ENGI FP) - Engie Brasil Energia is working with Banco Itau BBA and Banco Santander Brasil on an additional equity offering of up to BRL 10bln, Bloomberg reports. Proceeds would help finance the acquisition of a 40% stake in Jirau Energia from controlling shareholder Engie Brasil Participacoes.
EssilorLuxottica (EL FP) - EssilorLuxottica heir Leonardo Maria Del Vecchio agreed to buy two siblings’ stakes in family holding company Delfin for about EUR 10bln, Bloomberg reports. Six of Delfin’s eight shareholders approved the sale of the 25% combined holding, making Del Vecchio the largest single investor. (Bloomberg)
GSK (GSK LN) - Co. announced that the US Food and Drug Administration (FDA) has accepted for priority review a New Drug Application (NDA) for bepirovirsen, an investigational antisense oligonucleotide (ASO), for the treatment of adults with chronic hepatitis B (CHB). (GSK)
Ferrexpo (FXPO LN) - Update on funding options; delays 2025 financials, and shares will be suspended on 1 May 2026. (Ferrexpo)
Howden Refinery (HWDN LN) - Q1 Trading Update: Revenue +3.7% Y/Y. (Newswires)
Rolls-Royce (RR/ LN) - SCMP reports that the Co. has increased its presence in China with an engine venture. (SCMP)
Stellantis (STLAM IM/STLAP FP) - Co. is reportedly in talks with China's Hongqi, to build vehicles at Spanish plants, Reuters reports citing sources. (Reuters)
Sobi (SOBI SS) - Q1 2026 (SEK): Revenue 7.18bn (exp. 7.13bln), Adj. EBITA 2.750bln (prev. 2.260bln Y/Y). Adj. EBITA margin 38% (prev. 36% Y/Y). FY guidance unchanged. (Sobi)
STMicroelectronics (STMPA FP) - Co. brings always-on vision to next-generation personal electronics with new ultralow-power image sensors. (STMicroelectronics)
Taylor Wimpey (TW/ LN) - Trading Statement (GBP): Order Book 2.29bln (prev. 2.33bln Y/Y), Final Dividend for 2025: 2.95p/shr, and buyback of GBP 34.9mln. (Taylor Wimpey)
WPP (WPP LN) - Trading Update: FY Adj. Revenue 2.26bln (exp. 2.23bln); affirms outlook. (WPP)
Zealand Pharma (ZEAL DC) - Co. announced that Boehringer Ingelheim has reported positive topline results from the Phase III SYNCHRONIZE-1 trial, in which survodutide met the co-primary endpoints using both the efficacy and treatment-regimen estimands. (Zealand Pharma)
Avolta (AVOL SW) downgraded to Neutral from Buy at UBS
Balfour Beatty (BBY LN) initiated with Neutral at BNP Paribas
Diploma (DPLM LN) initiated with Outperform at BNP Paribas
Soitec (SOI FP) downgraded to Neutral from Outperform at Oddo
SSP (SSPG LN) downgraded to Neutral from Buy at UBS
Siemens (SIE GY) upgraded to Buy at HSBC
Saint Gobain (SGO FP) upgraded to Outperform from Sector Perform at RBC